The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function

Behavioural Pharmacology

Volumn 10, Issue 1, 1999, Pages 63-71

  Dall'Olio, R ^a   Gaggi, R ^a   Bonfante, V ^a   Gandolfi, O ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

( )5HTP; ( )sulpiride; 8 OH DPAT; CGP 43487; Dizocilpine; DOI; Ketanserin; SCH 23390; Serotonin mediated responses

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DIZOCILPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; KETANSERIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN 1A AGONIST; SEROTONIN 2A AGONIST; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; RAT; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033010654     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199902000-00006     Document Type: Article

References (44)

1. Alexander JE, Crutcher MD (1990). Functional architeture of basal ganglia circuits; neuronal substances of parallel processing. Trends Neurosci 13:266-271.
2. 2 agonist DOI. Eur J Pharmacol 161:45-51.
3. Bedard P, Pycock CJ (1977). 'Wet dog' shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity. Neuropharmacology 16:663-670.
4. Beloucif S, Keegan MJ, Galloway MP (1993). Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 265:373-377.
5. Berendsen HHG, Broekkamp CLE (1990). Behavioral evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol 101:667-673.
6. Björk L, Fredriksson A, Hacksell U, Levander T (1992). Effects of (R)-8-OH-DPAT and the enantiomers of UH-301 on motor activities in the rat: antagonism of (R)-8-OH-DPAT-induccd effects. Eur J Neuropsychopharmacol 2:141-147.
7. Bleich A, Brown SL, Kahn R, van Praag HM (1988). The role of serotonin in schizophrenia. Schizophenia Bull 14:287-315.
8. Carlsson M, Carlsson A (1990). Interaction between glutamatergic and monoaminergic systems within the basal ganglia-implication for schizophrenia and Parkinson's disease. Trends Neuro Sci 13:272-276.
9. Carlsson A, Hansson LO, Waters N, Carlsson ML (1997). Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 61:75-94.
10. Chapman CD, Gazzara RA, Howard SG (1990). Effects of phencyclidine on extracellular levels of dopamine, dihydrophenylacetic acid and homovanillic acid in conscious and anesthetized rats. Neuropharmacology 29:319-325.
11. Dall'OIio R, Roncada P, Vaccheri A, Gandolfi O, Montanaro N (1989). Synergistic blockade of some dopamine-mediated behaviours by (-)-sulpiride and SCH 23390 in the rat. Psychopharmacology 98:342-346.
12. Dall'Olio R, Gandolfi O, Montanaro N (1992). Effect of chronic treatment with dizocilpine (MK 801) on the behavioral response to dopamine receptor agonists in the rat. Psychopharmacology 107:591-594.
13. Dall'Olio R, Rimondini R, Gandolfi O (1995). The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function. Psychopharmacology 118: 310-315.
14. 2 mediated behaviors in intact rats. Psychopharmacology 123:187-190.
15. Dall'Olio R, Rimondini R, Gandolfi O (1997). Effects of competitive and non-competitive NMDA receptor antagonists on behavioral responses induced by 7-OH-DPAT and quinpirole in rats. Pharmacol Res 36:203-209.
16. 2 receptors? Pharmacol Biochem Behav 36:901-906.
17. Dawbarn D, Pycock CJ (1981). Motor effects following application of putative excitatory amino acid antagonists to the region of the mesencephalic dopamine cell bodies in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 318:100-104.
18. 1A receptor agonists on locomotor activity in the guinea-pig. Br J Pharmacol 112:861-866.
19. 2 receptors. Eur J Pharmacol 255:203-213.
20. Gleason SD, Shannon HE (1997). Blockade of phencyclidine-induced hyperlocomotion by olanzepine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129:79-84.
21. Glennon RA (1987). Central serotonin receptors as targets for drug research. J Med Chem 30:1-12.
22. Glennon RA, Darmani NA, Martin BR (1991). Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents. Life Sci 48:2493-2498.
23. Hjörth SA, Carlsson P, Lindberg P, Sanchez D, Wikstrom H, Arvidsson LE, Hacksel U, Nilsson JLG (1982), 8-Hydroxy-2-(di-n-propylamino) tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity. J Neural Trans 55:169-188.
24. Iyer RN, Bradberry CW (1996). Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterisation. J Pharmacol Exp Ther 277:40-47.
25. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE (1993). Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8:315-336.
26. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:374-382.
27. Löscher W, Hönack D (1992). The behavioral effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacol 215:199-208.
28. Löscher W, Annies R, Hönack D (1993). Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neural activity and behavioural effects in rats. Eur J Pharmacol. 242:263-274.
29. Lejeune F, Gobert A, Rivet JM, Millan MJ (1994). Blockade of transmission at NMDA receptors facilitates the electrical and synthetic activity of ascending serotonergic neurones. Brain Res 656:427-431.
30. Liljequist S (1991). Genetic differences in the effects of competitive and non-competitive NMDA receptor antagonists on locomotor activity in mice. Psychopharmacology 104:17-21.
31. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF (1962). Model psychoses and schizophrenia. Am J Psychiatry 119:61-65.
32. Matthews WD, Smith CD (1980). Pharmacological profile of a model for central serotonin receptor activation. Life Sci 26:1397-1403.
33. Meltzer HY (1989). Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27.
34. Murray TF, Horita S (1979). Phencyclidine-induced stereotyped behavior in rats: dose-response effects and antagonism by neuroleptics. Life Sci 24:2217-2226.
35. Ouagazzal A, Nielloun A, Amalric M (1993). Effects of dopamine D1 and D2 receptor blockade on MK-801 induced hyperlocomotion in rats. Psychopharmacology 111:427-434.
36. 2A receptors in antipsychotic activity. Life Sci 56:2209-2222.
37. 1A selective drugs on the 5-HT behavioural syndrome. Pharmacol Biochem Behav 24:1513-1519.
38. Snyder SH (1988). Psychotogenic drugs as model of schizophrenia. Neuropsychopharmacology 1:197-199.
39. 2 receptor-dependent locomotion by glutamate antagonists in reserpine-treated mice. Eur J Pharmacol 250:230-246.
40. 2 dopamine agonists in reserpine-treated mice. Psychopharmacology 114:469-476.
41. Starr MS, Starr BS (1994b). The new competitive NMDA receptor antagonist CGP 40116 inhibits pilocarpine-induced limbic motor seizures and unconditioned motor behavior in the mouse. Pharmacol Biochem Behav 47:127-131.
42. 1 receptor and of catecholaminergic systems in the behavioral response to 8-hydroxy-2-(dl-n-propylamino) tetralin in the rat. Eur J Pharmacol 106:271-282.
43. Verma A, Kulkarni SK (1992). Modulation of MK-801 response by dopaminergic agents in mice. Psychopharmacology 107:431-436.
44. Whitton PS, Biggs CS, Pearce BR, Fowler LJ (1992). MK-801 increases extracellular 5-hydroxytryptamine in rat hippo-campus and striatum in vivo. J Neurochem 58:1573-1575.